CONCIZUMAB

UNII: 68603V9EAF
Preferred Substance Name: CONCIZUMAB

1312299-39-0
CONCIZUMAB [INN]
CONCIZUMAB [JAN]
CONCIZUMAB [USAN]
CONCIZUMAB [WHO-DD]
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS TFPI (TISSUE FACTOR PATHWAY INHIBITOR, LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR)), HUMANIZED MONOCLONAL ANTIBODY
MAB2021
MAB-2021
NN7415
NN-7415
NNC-0172-0000-2021
NNC01722021
NNC0172-2021
NNC172-2021

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

CONCIZUMAB

Synonyms and Mappings

Resources

Note